Because the ARF–topo I interaction may be relevant to a large fraction of cancers, arising as a consequence of chronic CK2 elevation and oncogene activation, we have further examined the molecular events controlling this interaction and the consequences for topo I function. The gene discussed is CDKN2A; the disease is cancer.